Salarius Pharmaceuticals Issued U.S. Patent No. 11,773,080 Titled "Deuterium-Enriched Isoindolinonyl-Azepanediones And Related Compounds And Methods Of Treating Medical Disorders Using Same"
Portfolio Pulse from Benzinga Newsdesk
Salarius Pharmaceuticals has been granted U.S. Patent No. 11,773,080, which provides composition-of-matter protection until 2039 for its novel molecular glues. This addition expands the company's protein degrader portfolio to include 17 issued patents across six patent families.
January 16, 2024 | 1:16 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Salarius Pharmaceuticals' new patent strengthens its intellectual property portfolio, potentially enhancing its market position and investor confidence in its novel molecular glues technology.
The issuance of a new patent typically has a positive impact on a pharmaceutical company's stock as it secures exclusive rights to its technology, which can lead to a competitive advantage and potentially higher future revenues. The protection until 2039 is significant, indicating long-term control over the patented technology.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100